Support from readers like you keeps The Journal open. You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to ...

Several headwinds are impacting the company, including generic competition for its blockbuster drug Stelara, the ongoing talc lawsuit (which could see a final decision in the first half of the ...

Overall, global Stelara sales dropped 14.7% year-over-year to roughly $2.3 billion in 2024’s fourth quarter. For the full 12-month earnings period, Stelara sales slipped around 4.6% to $10.4 ...

Investors are watching biosimilar competition with immunology drug Stelara, which extended to the key US market in January. We assume a more than $3 billion decline in global Stelara sales in 2025.

Using a single PBM as the sole distribution channel is unprecedented. Without a lot of fanfare or a news release, Wezlana (ustekinumab-auub), the first Stelara (ustekinumab) biosimilar has hit the ...

A man in his 30s has been found dead inside a house in Swindon following the discovery of an 'unidentified vial of liquid'. Emergency services rushed to a house on Collett Avenue at around 4 ...

Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the ...

BECKLEY, W.Va. — An FBI chemist who tested a vial found in accused murderer Natalie Cochran’s refrigerator after the death of her husband testified Friday what was in the vial was consistent ...

Will the Stelara biosimilars be a reprise of the Humira biosimilars in 2023 and be slow to catch on? Biosimilar watchers circled 2023 as a red-letter year because that was the year that the Humira ...